Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
December 21, 2018 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – December 21, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical- stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
December 07, 2018 12:12 ET
|
ObsEva SA
Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December...
ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
December 06, 2018 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – December 6, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA to Host R&D Investor Day December 7, 2018
November 29, 2018 01:30 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
November 28, 2018 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
November 08, 2018 01:15 ET
|
ObsEva SA
IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase 2b EDELWEISS clinical trial of linzagolix in endometriosis supports 75mg...
ObsEva SA to Participate in November Investor Conferences
November 07, 2018 01:30 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – November 7, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018
October 31, 2018 02:30 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA –October 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
October 09, 2018 16:15 ET
|
ObsEva SA
Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate (LBR) in...
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
October 05, 2018 01:00 ET
|
ObsEva SA
Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA - October 5, 2018- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a...